Clinical cases

Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel. A brief description of the cases can be found below.

case 1 (part of module 1)

Younger fit patient with relapse after high-dose therapy with autologous stem cell transplantation

Agoston Gyula Szabo, MD

Department of Hematology, Rigshospitalet Copenhagen, Denmark

case 2 (part of module 1)

Younger fit patient with relapse after high-dose therapy with autologous stem cell transplantation

Inger Nijhof, MD, PhD

Department of Internal Medicine, St. Antonius Hospital, The Netherlands

case 3 (part of module 1)

A patient refractory to lenalidomide and non-responsive to bortezomib

Fredrik Schjesvold, MD, PhD

Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway

case 4 (part of module 1)

Patient with early relapse after auto-SCT

Ville Varmavuo, MD PhD

Chief Medical Officer in Education, Internal Medicine, Kotka, Finland

case 5 (part of module 1)

Patient beyond the third line: carfilzomib, lenalidomide, pomalidomide, and anti-CD38 refractory

Valdas Peceliunas, MD

Department of Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

case 6 (part of module 1)

Second line treatment in early relapse

Professor Xavier Leleu, MD, PhD

Department of Hematology, Academic Hospital of Poitiers, France

case 7 (part of module 2)

Early relapse following initial therapy for MM predicts poor outcome, even in the era of novel agents

Isabelle Vande Broek, MD, PhD

Department of Internal Medicine, St. Antonius Hospital, The Netherlands

case 8 (part of module 2)

Extramedullary disease in multiple myeloma: a challenging therapeutic dilemma

Department of Oncology & Hematology, Vitaz, Sint-Niklaas, Belgium

Department of Oncology & Hematology, Vitaz, Sint-Niklaas, Belgium

Disclaimer: The purpose of this e-learning is to provide you as an HCP with relevant information on the basis of which you can draw your own conclusions. This information is not intended to provide recommendations regarding indications, dosages, or other statements not listed in the Summary of Product Characteristics of the products concerned or not listed in the local applicable guidelines for multiple myeloma.